General Anesthesia Drugs, also known as general anaesthetics, is a kind of drug that can inhibit the central nervous system function, make the consciousness, feeling and reflection temporarily disappeared, skeletal muscle relaxation, mainly used for anesthesia before surgery.
Figure Theories of General Anaesthetic Action
COVID-19 outbreak will affect upstream, midstream, downstream of General Anesthesia Drugs in many ways. The promotion effect of short-term occupant economy factors in General Anesthesia Drugs market is obvious.
Figure Upstream, Midstream, Downstream of General Anesthesia Drugs
The major General Anaesthetic player in the market
- Astrazeneca
- Fresenius-Kabi
- Abbott
- Bayer
- AbbVie
- Baxter Healthcare
- B.Braun
- Maruishi
- Piramal
- Hikma Pharmaceuticals
- Mylan
- Lunan
- Humanwell Healthcare
- Nhwa Pharmaceutical
- Guangdong Jiabo Pharmaceutical
- Sichuan Guorui Pharmaceutical
- Xi’an Libang Pharmaceutical
- Sichuan Kelun Pharmaceutical
- Hengrui Pharmaceutical
- Shanghai United Imaging Healthcare
- Wandong Medical Technology
Get PDF report template @ https://www.qyresearch.com/sample-form/form/1661623/global-general-anaesthetics-key-trends-and-opportunities-to-
The major Propofol Drug player in the market
- Pfizer
- Teva Pharmaceutical Industries
- Fresenius Kabi AG
- B. Braun Melsungen AG
- AstraZeneca Plc
- SGPharma
- Baxter international
- Sichuan Guorui Pharmaceutical
- Guangdong Jiabo Pharmaceutical
- Nhwa Pharmaceutical
- Xi’an Libang Pharmaceuticall
Compared with the traditional ketamine based anesthesia, sevoflurane anesthesia has the advantages of calm in the induction period, stable hemodynamics during the operation, small dosage of muscle relaxants, fast postoperative recovery, and more thorough awakening. But agitation during induction and recovery is a problem to be overcome. Immediate discomfort after rapid awakening is an important cause of postoperative restlessness, so combining small amounts of imidazole and fentanyl may delay the patient’s recovery but may improve the quality of recovery.
The major Sevoflurane (Sevoflurane Source) player in the market
- Abbott
- Baxter
- Maruishi Pharmaceutical
- Jiangsu Hengrui
- Lunan
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia.
The major Midazolam player in the market
- Roche
- Pfizer
- Apotex Corporation
- West-Ward Pharmaceuticals Corp
- Alvogen
- Akorn
- Nichi-Iko
- Zhejiang Jiuxu Pharmaceutical
- Nhwa Pharmaceutical
- Humanwell Healthcare
Figure Global Production Market Share of General Anesthesia Drugs by Type
Globally, North America dominates the narcotics market. The United States narcotics market is the largest regional market in the world. The market is driven by factors such as an increase in the number of surgeries, an aging population and an increase in chronic diseases, as well as advances in anesthesia.
Figure Global General Anesthesia Drugs Market Share by Regions
The General Anesthesia Drugs market in the Asia-pacific region is expected to grow at a significant rate Under COVID- 19, The Asian market is expected to return to high growth in 2020 and beyond with Coronavirus COVID- 19 Global Cases and COVID-19 Outbreak Evolution trend.
The industry has entered a new era with broad space for future growth in China.
On the one hand, China’s population aging process is accelerating: the proportion of the aged population over 65 years old in 18 years has reached 11.9%, which is 2.2pp higher than 5 years ago and 3.8pp higher than 10 years ago.
On the other hand, the unprecedented reform of drug review encourages drug device innovation to rise to the national level and gradually integrate with the international standard, leading the industry to enter a new era of innovation.
At the same time, the early marketing of innovative drugs to make money effect prominent, play a good demonstration effect.
At the same time, a total of 36 bio-pharmaceutical companies have applied for the scientific innovation board, of which 4 have submitted for registration and 16 have become effective.
Figure Coronavirus COVID- 19 Global Cases
However, the COVID-19 epidemic has entered the period of COVID-19 in Europe and America, As of 8 o ‘clock on April 16, global countries had confirmed 2, 088,636 cases, with 1, 437,945 new cases confirmed, and 134,754 more than 130,000 cases died. The number of confirmed cases and deaths in overseas countries were far higher than that in China. Europe and the United States have been the hardest hit: the United States is the world’s largest country with more than 600,000 confirmed cases, with a total of 644,348 confirmed cases. There were 259 new confirmed cases and 25 new deaths compared to April 15, 2020.
Figure: COVID-19 Outbreak Evolution for the Most Affected Countries
In March 2020, Humanwell Healthcare has just been approved the regulated alfentanil, and there are other regulated varieties such as oxymorphone, and M6G injection in the following varieties.
The major players such as Hengrui pharmaceutical, Humanwell Healthcare have all achieved rapid growth in the past (much faster than the industry average), with extremely high gross margins and profitability in China.
In 2019, the revenue of anesthesia line was 4.05 billion, and the CAGR of 10 years was 22.83%, which was also a continuous 10 years of super-fast growth, and the gross profit rate was close to 90%.Before 2008, the company owned fentanyl, remifentanil, sufentanil and other regulated varieties at the same time. In 2012 and 2013, Humanwell Healthcare was approved to regulate hydromorphone and nabulphine respectively, enjoying the monopoly dividend brought by high administrative barriers.
Figure Global General Anesthesia Drugs Sale and Growth Rate (K L)
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global General Anaesthetics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global General Anaesthetics market in terms of revenue.
Players, stakeholders, and other participants in the global General Anaesthetics market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global General Anaesthetics market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global General Anaesthetics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global General Anaesthetics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global General Anaesthetics market.
The following players are covered in this report:
- Astrazeneca
- Fresenius-Kabi
- Abbott
- Bayer
- AbbVie
- Baxter Healthcare
- B.Braun
- Maruishi
- Piramal
- Hikma Pharmaceuticals
- Mylan
- Lunan
- Humanwell Healthcare
- Nhwa Pharmaceutical
- Guangdong Jiabo Pharmaceutical
- Sichuan Guorui Pharmaceutical
- Xi’an Libang Pharmaceutical
- Sichuan Kelun Pharmaceutical
- Hengrui Pharmaceutical
- Shanghai United Imaging Healthcare
- Wandong Medical Technology
Request Customization of Report @ https://www.qyresearch.com/customize-request/form/1661623/global-general-anaesthetics-key-trends-and-opportunities-to-
General Anaesthetics Breakdown Data by Type
by Drug Type
- Propofol
- Sevoflurane
- Etomidate
- Midazolam
- Isoflurane
- Other
by Delivery Drug Way
- Intravenous Anesthetics
- Inhalational Anesthetics
General Anaesthetics Breakdown Data by Application
- Emergency Room
- Operating Room
- ICU
- Surgical
- Oncology
About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
Contact US
QY Research, INC.
17890 Castleton, Suite 218,
Los Angeles, CA – 91748
USA: +1 626 428 8800
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478 224
